The partnership will boost dialysis laboratory testing and lower the laboratory costs of dialysis programs for ESRD patients. Credit: Hospital Mon/Shutterstock.com.

Neway has announced a strategic lab services arrangement with Quest Diagnostics to speed up dialysis laboratory testing and lower dialysis programme laboratory costs for end-stage renal disease (ESRD) patients.

As per the agreement terms, Neway will access Quest’s lab network to deliver local dialysis laboratory testing services with next-day results after arrival.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Quest’s distributed lab network will allow Neway and its affiliated dialysis centres to quickly complete testing and deliver results with reduced transportation costs.

The partnership will offer an alternative to the centralised lab model under which specimens from several dialysis programmes in the US are transported to a single laboratory for processing.

Neway founder and CEO Bryan Thompson said: “The old model of generally relying on air transportation of dialysis laboratory specimens to a single US location is costly and can take days for results.

“The ‘new way’ for dialysis laboratory testing is a decentralised network of laboratory locations that spans the nation. This approach is good for dialysis patients, dialysis programmes, insurance payers and the entire dialysis industry.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Available through Quest’s subspecialty pathology business AmeriPath, the tissue-based test service helps meet the critical clinical requirement for detecting and distinguishing potentially aggressive prostate cancer cases in men.

In July of this year, Quest and Envision Sciences announced a partnership to launch a new prostate cancer biomarker test.